AC Immune's 1H Update: 18 More Months of Cash, but the Real Bet Is Still Downstream

The cash extension is the quiet but most immediate takeaway

The most useful part of this update is not flashy: ACImmune has extended its runway to Q4 2027, buying roughly 18 months before financing becomes the main question. For a clinical-stage biopharmaceutical company with no product revenue yet, that matters. The cash does not prove the science, but it preserves the company's chance to do so.

Why a quiet funding update matters

The balance-sheet takeaway starts with cash resources of CHF 74.8 million as of March 31, 2026. In practical terms, that keeps operations running and gives the next clinical readouts more time to speak for themselves.

The other part of the story is outside validation. ACImmune says its alliances have already generated more than CHF 450 million in funding and include over CHF 4 billion in potential milestones. That does not replace clinical proof, but for a pre-revenue biotech it is a meaningful credibility signal.

Clinical progress, not the income statement, is the real scorecard

For a company this early, the income statement is mostly background noise. What matters is whether any programme is getting closer to showing real value in people. On that front, the first-half update did move the story forward.

Alzheimer's remains the core, but the pipeline is broadening

Alzheimer's is still ACImmune's lead narrative. Earlier this spring, the company initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease, and that initiation triggers milestone payment, as announced separately today. ABATE is also approaching 12-month interim results of the AD3 cohort in ABATE in Q2 2026. That is the kind of data event investors can actually judge: does Tau aggregation inhibition show a durable signal over a full year?

The breadth of the story is also expanding. The company amended Morphomer® Tau collaboration with Lilly, which suggests ongoing partner confidence in that programme. And ACImmune dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764, with SAD/MAD results in healthy volunteers expected in H2 2026. That does not prove a new pillar yet, but it does suggest the company is testing more than a single proteinopathy pathway.

Diagnostics and Parkinson's add optionality

ACImmune is also expecting full data from Part 1 of ACI-7104 VacSYn Phase 2 trial in H2 2026, which could give investors an earlier look at the company's diagnostic and antibody work. Separately, the company later presented new Phase 1 data in Parkinson's disease and to receive research grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease. That does not confirm therapeutic promise, but it does reinforce the idea that ACImmune is building a broader neurodegeneration franchise rather than leaning on one program alone.

Partner backing helps, but clinical proof still decides the story

The extended runway changes the debate, but it does not settle it.

Why partner validation matters

Bulls have a reasonable case here: this is not a one-lab science experiment. ACImmune has multiple strategic alliances with leading industry partners like Takeda, Janssen Pharmaceuticals, Inc. (a Johnson & Johnson company) and Eli Lilly and Company, has received more than CHF 450 million in funding from those relationships, and has over CHF 4 billion in potential milestones. That kind of backing suggests experienced partners see value in the targets and the technology.

Why bears are not wrong to stay patient

But partner support is not the same as clinical proof or commercial demand. The milestone pipeline is still potential, not realized value. And breadth can cut both ways: investors may like the idea of a multi-disease platform, yet still wait for cleaner evidence from one lead program before assigning much value to the rest of the pipeline.

What to watch over the next few quarters

• Alzheimer's: the 12-month interim results of the AD3 cohort in ABATE and continued progress in the final cohort.
• NLRP3:SAD/MAD results in healthy volunteers expected in H2 2026 from the ACI-19764 Phase 1 trial.
• Diagnostics and Parkinson's:full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 and any follow-through on the research grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease.

What improves or weakens the case

The thesis gets stronger if Alzheimer's data shows a credible signal and the newer programs keep advancing without major noise. It gets weaker if the company keeps broadening the story while the core clinical evidence remains unsettled.

For now, the setup is straightforward: funding into Q4 2027 and multiple strategic alliances with leading industry partners reduces near-term financing pressure, but the next meaningful re-rating still depends on clean, interpretable clinical proof.